Company intelligence / Profile preview

ReqMed Company, Ltd.

Machida-City, Tokyo, Japanreqmed.co.jp ↗

Ownership: Private
Employees: ~20
Development stage: Preclinical

Overview

The company has successfully developed and commercialized Cystadan® bulk powder (betaine) for homocystinuria, and has conducted multiple Phase II and Phase III clinical trials for various indications including PPS for OsteoArthritis, HTLV-1 Associated Myelopathy, and MucoPolySaccharidosis.

Therapeutic areas: Rare DiseasesNeurologyMetabolic DisordersRheumatology
Modalities: Small molecule drugsPolymer
Industry: Biotech

Drug pipeline

1 asset

betaine anhydrous

Approved

Partnerships

Kyowa Hakko Kogyo Co., Ltd.PsychoGenics, Inc.bene pharmaChem GmbH & Co. KGChong Kun Dang Pharmaceutical Corp.Orphan Europe SARLIcahn School of Medicine at Mount Sinai

Beyond the preview

Go deeper on ReqMed Company, Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReqMed Company, Ltd..

Explore the full profile